Large pooled analysis found no clear rise in major birth defects after early pregnancy exposure to GLP-1 drugs

# Summary

# What researchers did

# Main findings Across the combined studies, there was no statistically significant increase in congenital malformations among pregnancies exposed to GLP-1 drugs compared with control groups. When analyses focused specifically on major congenital malformations and on exposures during the first trimester—the period of most active organ formation—researchers again did not identify a statistically significant increase.

# What this means for patients and clinicians These results offer context for women who took a GLP-1 medication before they knew they were pregnant. An accidental early exposure does not automatically mean a major birth defect will occur. The pooled evidence provides more human data beyond animal studies and small case reports that previously informed concern.

However, the absence of a statistically significant increase is not the same as proof of safety. The studies were observational cohorts, not randomized trials. That means women were not randomly assigned to take GLP-1 drugs during pregnancy, and the analyses cannot account for every difference between exposed and unexposed groups.

# Important limitations

• Observational design: cohort studies can be affected by confounding factors related to why someone was prescribed a GLP-1 drug (for example, diabetes versus weight management) and by other health differences.
• Heterogeneity: studies likely varied in the specific GLP-1 drug used, dose, timing and duration of exposure, and outcome definitions. Those differences can dilute or mask signals.
• Statistical interpretation: "no statistically significant increase" means the pooled data did not show a clear excess of risk large enough to rule out chance. It does not demonstrate equivalence.

# Practical takeaways and next steps

• If a patient discovers she took a GLP-1 drug before knowing she was pregnant, these pooled data can be used to provide cautious reassurance that an automatic major birth-defect outcome is unlikely based on current evidence.
• Clinicians should discuss the limits of the evidence: observational data, varying exposures, and remaining uncertainty about intentional use in pregnancy.
• Decisions about stopping medication, additional testing, or specialist referral should be individualized, taking into account the specific drug, timing of exposure, underlying medical conditions, and patient preferences.

# Bottom line Pooling seven cohort studies with more than 40,000 GLP-1–exposed pregnancies did not find a clear signal of increased overall or major congenital malformations after conception or first-trimester exposure. The evidence reduces some immediate uncertainty about accidental early exposure but does not establish that GLP-1 drugs are safe to start or continue during pregnancy.